Pfizer Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Exclusive Supply and Marketing Agreement for Pfizer Limited s brands Corex Dx,Corex LS, Dolonex, and Neksium with Cipla Limited.".
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pfizer Limited has signed an exclusive supply and marketing agreement with Cipla Limited for four of its established pharmaceutical brands: Corex Dx, Corex LS, Dolonex, and Neksium. Under this arrangement, Cipla will handle the supply chain and marketing for these brands in India. This is a significant portfolio move, as these are legacy, well-known brands in the Indian pharma market, particularly in the cough, cold, and pain/gastro segments. The deal allows Pfizer to streamline its commercial focus while Cipla expands its branded portfolio.
For shareholders, this signals a strategic shift toward focusing on Pfizer's innovative and specialty portfolio, with legacy brands now monetized through a partnership model. Near-term revenue from these brands will transition to Cipla, but the deal could unlock better margins and free up resources for higher-growth therapeutic areas.